ERBB2 and cancer: While CB2 agonists may promote tumor progression via their immunosuppressive effects, the receptor has also been demonstrated to promote cancer progression and metastasis through forming heteromers with epidermal growth factor receptor-2 (HER2) and CXCR4 (66, 67).